Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, PK, and PD of TAVO103A in Healthy Adults
NCT05313152Phase 1Completed
- Sponsor
- Tavotek Biotherapeutics
- Start
- Apr 2022
- Primary completion
- Apr 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TAVO103A in chronic inflammation and autoimmune diseases (4 arms), sponsored by Tavotek Biotherapeutics. Primary endpoints: Severity of adverse effects according to CTCAE and Changes in vital signs. Started Apr 2022; status: completed.
02
Drugs
TAVO103A
03
Conditions
chronic inflammationautoimmune diseases
Beyond the preview
Go deeper on NCT05313152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05313152.